Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

European Journal of Hybrid Imaging

卷:2

Sofia Levva¹  Savvas Frangos²  Areti Gkantaifi³  Evanthia Giannoula⁴  Ioannis Iakovou⁴ 

[1] Department of Medical Oncology, Papageorgiou General Hospital, School of Health Science Faculty of Medicine, Aristotle University of Thessaloniki;

[2] Department of Nuclear Medicine, Bank of Cyprus Oncology Centre;

[3] Radiotherapy Department, Interbalkan Medical Center;

[4] Third Department of Nuclear Medicine, Medical School, Aristotle University of Thessaloniki, Papageorgiou General Hospital;

关键词: Breast cancer;    Nuclear medicine;    Molecular imaging;    Positron emission tomography (PET);    Immunohistochemistry;    Radiopharmaceuticals;   

DOI  :  10.1186/s41824-018-0039-x

来源: DOAJ

【 摘 要 】

Abstract Background Breast cancer heterogeneity reflects the complex biology of this disease. Breast cancer subtypes, as identified either by immunohistochemistry (IHC) or by gene expression analysis, present different molecular characteristics and prognosis. In this context, molecular imaging techniques providing functional information, contribute in evaluating response to treatment and long-term prognosis among different subtypes. Nuclear imaging diagnosis modalities play an important role for conducting research on cancer biology and developing new treatment approaches. Positron Emission Tomography (PET) is a radionuclide based imaging method that has the potential to locate the tumor, define its staging, and monitor its response to treatment. Results In the current study, we will review the utility of the most widely used molecular imaging technique, 18F-fluorodeoxyglucose (18F-FDG) PET, in order to determine the relationship between standardized uptake values (SUVs) and immunohistopathological factors, as well as to clarify whether PET is able to predict breast cancer phenotypes. Moreover, we will discuss the rising development of new radiopharmaceuticals in PET imaging, such as 18F-fluoro-17-estradiol (FES), 18F-fluoro-l-thymidine (FLT), 18F-fluoromisonidazole (FISO), and 89Zr-immuno-PET, which give more information about tumor characteristics. Conclusions In order to improve clinical decision making, enabling hereafter more successful individualized therapies, it is imperative to combine PET radiopharmaceuticals and imaging techniques of critical biologic and pathologic phenomena, including ER, PR and HER2 expression, angiogenesis, hypoxia, apoptosis and metabolic changes in the microenviroment of breast tumors.

【 授权许可】

Unknown